Linnea Bergenholm

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease.

Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease.

Journal: Scandinavian journal of gastroenterology

Published: June 03, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.

Journal: Circulation

Published: May 15, 2026

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.

Journal: Circulation

Published: May 15, 2026

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.

AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.

Journal: Journal of hepatology

Published: August 20, 2024

A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.

A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 21, 2023

Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.

Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.

Journal: Hepatology communications

Published: February 10, 2022

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers.

Chronic Oral Administration of Mineral Oil Compared With Corn Oil: Effects on Gut Permeability and Plasma Inflammatory and Lipid Biomarkers.

Journal: Frontiers in pharmacology

Published: March 17, 2021

Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs.

Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: October 19, 2020

A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.

Journal: Journal of pharmacokinetics and pharmacodynamics

Published: November 15, 2017

Parameter Identifiability of Fundamental Pharmacodynamic Models.

Parameter Identifiability of Fundamental Pharmacodynamic Models.

Journal: Frontiers in physiology

Published: August 31, 2016

Predicting QRS and PR interval prolongations in humans using nonclinical data.

Predicting QRS and PR interval prolongations in humans using nonclinical data.

Journal: British journal of pharmacology

Published: July 28, 2016

PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data.

PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data.

Journal: Journal of pharmacological and toxicological methods

Published: August 20, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026